Profile data is unavailable for this security.
About the company
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC) and is also in development for the treatment of additional tumor types. Its CHS-114 pipeline is a highly selective cytolytic CCR8 antibody that specifically binds and preferentially depletes CCR8+ tumor regulatory T cells (Tregs) with no off-target binding. Its Casdozokitug pipeline is a first-in-class, clinical-stage IL-27 antagonist, with demonstrated monotherapy activity in treatment-refractory NSCLC and clear cell renal cell carcinoma (ccRCC) and combination activity in hepatocellular carcinoma (HCC).
- Revenue in USD (TTM)83.57m
- Net income in USD-187.47m
- Incorporated2010
- Employees161.00
- LocationCoherus Oncology IncC/O DENNIS M. LANFEAR201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY 94065United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.coherus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fortress Biotech Inc | 62.30m | -5.34m | 112.05m | 101.00 | -- | 2.00 | -- | 1.80 | -0.293 | -0.293 | 2.16 | 1.80 | 0.4039 | 1.50 | 4.35 | 616,861.40 | -34.90 | -54.95 | -51.59 | -102.13 | 71.56 | 62.39 | -86.41 | -227.71 | 1.97 | -10.63 | 0.4503 | -- | -31.76 | 9.50 | 18.61 | -- | 25.88 | -- |
| Whitehawk Therapeutics Inc | 14.38m | -15.62m | 134.32m | 22.00 | 20.98 | 0.8546 | -- | 9.34 | 0.1358 | 0.1358 | 0.2802 | 3.33 | 0.1138 | 0.5669 | 4.40 | 359,600.00 | -12.36 | -52.97 | -13.76 | -60.63 | 89.22 | -- | -108.58 | -372.67 | 16.76 | -- | 0.00 | -- | 6.69 | -- | 3.15 | -- | 47.49 | -- |
| NDT Pharmaceuticals Inc | -100.00bn | -100.00bn | 152.00m | 1.00 | -- | 0.8486 | -- | -- | -- | -- | -- | 1.12 | -- | -- | -- | -- | -- | -164.47 | -- | -452.47 | -- | -- | -- | -6,891.36 | -- | -- | 0.00 | -- | -100.00 | -- | 87.56 | -- | -- | -- |
| Karyopharm Therapeutics Inc | 142.53m | -124.62m | 157.11m | 279.00 | -- | -- | -- | 1.10 | -14.58 | -14.58 | 16.69 | -30.94 | 0.9977 | 1.34 | 4.48 | 510,860.20 | -87.24 | -48.75 | -181.85 | -63.64 | 95.93 | 97.09 | -87.43 | -92.03 | 0.9842 | -2.55 | -- | -- | -0.5451 | 28.85 | 46.60 | -- | -7.17 | -- |
| Sanara Medtech Inc | 101.90m | -6.24m | 168.97m | 141.00 | -- | 27.47 | -- | 1.66 | -0.7292 | -4.34 | 11.86 | 0.6885 | 1.28 | 2.47 | 8.78 | 722,724.30 | -8.03 | -15.12 | -10.00 | -18.64 | 92.25 | 88.92 | -6.29 | -14.70 | 1.60 | 0.3039 | 0.8801 | -- | 33.36 | 49.09 | -124.59 | -- | -33.05 | -- |
| BGM Group Ltd | 26.85m | -2.72m | 178.70m | 323.00 | -- | 0.5937 | -- | 6.66 | -0.2816 | -0.2816 | 1.38 | 1.85 | 0.2087 | 3.21 | 8.60 | 83,116.91 | -2.08 | -0.0792 | -2.36 | -0.1065 | 19.41 | 10.38 | -9.95 | -0.0921 | 1.45 | -0.3408 | 0.0087 | 2,560.18 | -45.99 | -11.45 | 81.46 | -- | 16.40 | -- |
| Tonix Pharmaceuticals Holding Corp | 10.30m | -99.22m | 193.70m | 81.00 | -- | 0.666 | -- | 18.81 | -20.11 | -20.11 | 1.69 | 22.73 | 0.0593 | 0.9665 | 2.75 | 127,148.10 | -57.12 | -61.84 | -63.76 | -68.67 | 34.31 | -- | -963.38 | -2,797.35 | 9.62 | -- | 0.00 | -- | 29.94 | -- | -11.47 | -- | 47.82 | -- |
| Coherus Oncology Inc | 83.57m | -187.47m | 194.60m | 161.00 | -- | 2.13 | -- | 2.33 | -1.62 | 1.33 | 0.721 | 0.7551 | 0.1636 | 1.76 | 0.9453 | 366,526.30 | -36.70 | -21.44 | -106.02 | -31.54 | 47.79 | 71.26 | -224.34 | -42.66 | 1.23 | -15.12 | 0.3656 | -- | 3.78 | -5.60 | 111.98 | -20.51 | -- | -- |
| Journey Medical Corp | 59.40m | -8.66m | 210.69m | 41.00 | -- | 7.87 | -- | 3.55 | -0.3645 | -0.3645 | 2.58 | 0.982 | 0.796 | 1.79 | 4.15 | 1,448,756.00 | -11.61 | -22.37 | -22.74 | -50.55 | 64.40 | 59.45 | -14.58 | -27.43 | 1.12 | -3.30 | 0.4928 | -- | -29.11 | 9.96 | -280.79 | -- | 44.27 | -- |
| Mediwound Ltd | 20.93m | -20.60m | 221.66m | 111.00 | -- | 4.41 | -- | 10.59 | -1.90 | -1.90 | 1.93 | 3.91 | 0.2475 | 4.59 | 3.69 | 188,576.60 | -24.36 | -35.38 | -35.12 | -48.39 | 18.53 | 32.18 | -98.43 | -71.55 | 2.48 | -- | 0.1416 | -- | 8.22 | -8.65 | -350.03 | -- | 51.27 | -- |
| Opus Genetics Inc | 14.63m | -68.20m | 251.03m | 18.00 | -- | 39.37 | -- | 17.16 | -1.76 | -1.76 | 0.2952 | 0.0925 | 0.3825 | -- | 3.85 | 812,944.40 | -178.28 | -76.30 | -330.00 | -86.90 | -- | -- | -466.09 | -185.79 | -- | -- | 0.1518 | -- | -42.30 | -- | -476.13 | -- | -- | -- |
| Lifecore Biomedical Inc | -100.00bn | -100.00bn | 265.26m | 406.00 | -- | -- | -- | -- | -- | -- | -- | 0.9818 | -- | -- | -- | -- | -- | -7.91 | -- | -10.85 | -- | 32.86 | -- | -23.15 | 1.67 | -- | 0.787 | -- | 0.4725 | -4.24 | -575.39 | -- | -12.85 | -- |
| Abeona Therapeutics Inc | 400.00k | 82.35m | 271.50m | 136.00 | 4.53 | 1.53 | 3.21 | 678.75 | 1.11 | 1.11 | 0.0073 | 3.27 | 0.0023 | -- | 0.2478 | 2,941.18 | 46.83 | -62.23 | 52.94 | -78.23 | -122.00 | -- | 20,587.50 | -1,824.21 | 9.53 | -- | 0.1034 | -- | -100.00 | -- | -17.62 | -- | -17.78 | -- |
| Evolus Inc | 285.82m | -58.56m | 278.73m | 329.00 | -- | -- | -- | 0.9752 | -0.9125 | -0.9125 | 4.46 | -0.4441 | 1.27 | 4.09 | 6.01 | 860,912.60 | -26.11 | -37.04 | -36.48 | -57.14 | 65.83 | 65.19 | -20.49 | -51.26 | 1.53 | -2.13 | 1.25 | -- | 31.76 | 50.12 | 18.26 | -- | 1.10 | -- |
Data as of Feb 13 2026. Currency figures normalised to Coherus Oncology Inc's reporting currency: US Dollar USD
29.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 9.21m | 7.62% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 8.17m | 6.76% |
| Tang Capital Management LLCas of 30 Sep 2025 | 5.10m | 4.22% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.75m | 2.27% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 2.22m | 1.84% |
| CM Management LLCas of 31 Dec 2025 | 2.10m | 1.74% |
| C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Dec 2025 | 1.93m | 1.60% |
| PanAgora Asset Management, Inc.as of 31 Dec 2025 | 1.62m | 1.34% |
| BlackRock Advisors LLCas of 31 Dec 2025 | 1.33m | 1.10% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 935.24k | 0.77% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
